Karyopharm stock drops af­ter in­hibitor's PhI da­ta show low­er dose not as ef­fec­tive: #AACR23

Karyopharm Ther­a­peu­tics shared up­dat­ed Phase I da­ta for its oral XPO1 in­hibitor, which is be­ing test­ed as a treat­ment for myelofi­bro­sis in com­bi­na­tion with rux­oli­tinib, that found a high­er dose of the com­bi­na­tion ther­a­py im­proved symp­toms in 80% of pa­tients.

The news was an­nounced Tues­day at the Amer­i­can As­so­ci­a­tion for Can­cer Re­search, and Karyopharm’s stock $KP­TI was down about 3% in trad­ing on Wednes­day af­ter­noon.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.